Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ENTANASDAQ:OPTNASDAQ:ORICNASDAQ:RLAY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENTAEnanta Pharmaceuticals$5.32-3.6%$6.41$4.71▼$17.60$113.49M0.48278,630 shs185,351 shsOPTOpthea$3.41+7.2%$4.40$1.79▼$6.30$524.84M1.1226,023 shs3,000 shsORICORIC Pharmaceuticals$5.53-0.9%$8.66$5.26▼$14.67$392.78M1.25615,574 shs1.26 million shsRLAYRelay Therapeutics$2.47-5.7%$3.80$2.38▼$10.72$418.72M1.651.88 million shs2.73 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENTAEnanta Pharmaceuticals-3.33%-10.97%-29.05%-4.00%-68.38%OPTOpthea0.00%0.00%-23.88%-13.23%-17.03%ORICORIC Pharmaceuticals-9.12%-24.29%-30.51%-30.86%-59.42%RLAYRelay Therapeutics-3.68%-15.48%-23.17%-36.41%-68.43%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationENTAEnanta Pharmaceuticals3.8688 of 5 stars3.41.00.04.71.54.20.0OPTOpthea0.6952 of 5 stars2.11.00.00.01.50.80.6ORICORIC Pharmaceuticals4.0159 of 5 stars4.50.00.04.41.61.70.6RLAYRelay Therapeutics2.2006 of 5 stars3.51.00.00.02.52.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceENTAEnanta Pharmaceuticals 2.80Moderate Buy$17.25224.25% UpsideOPTOpthea 2.17Hold$1.33-60.90% DownsideORICORIC Pharmaceuticals 3.00Buy$18.86241.00% UpsideRLAYRelay Therapeutics 2.90Moderate Buy$19.80701.62% UpsideCurrent Analyst Ratings BreakdownLatest ENTA, RLAY, OPT, and ORIC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/25/2025OPTOptheaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$12.00 ➝ $2.003/25/2025OPTOptheaLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform$12.00 ➝ $1.003/25/2025OPTOptheaJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Underperform$8.00 ➝ $1.003/24/2025OPTOptheaLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold3/24/2025OPTOptheaOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform3/20/2025ORICORIC PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$20.003/7/2025RLAYRelay TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.002/28/2025OPTOptheaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.002/27/2025RLAYRelay TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$20.00 ➝ $18.002/27/2025RLAYRelay TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$27.00 ➝ $23.002/26/2025ORICORIC PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$21.00 ➝ $22.00(Data available from 4/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookENTAEnanta Pharmaceuticals$66.59M1.70N/AN/A$5.24 per share1.02OPTOpthea$87.67K5,986.77N/AN/A($0.56) per share-6.09ORICORIC PharmaceuticalsN/AN/AN/AN/A$3.42 per shareN/ARLAYRelay Therapeutics$10.01M41.84N/AN/A$5.90 per share0.42Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateENTAEnanta Pharmaceuticals-$116.04M-$4.95N/AN/AN/A-157.57%-75.53%-27.30%5/5/2025 (Estimated)OPTOpthea-$220.24MN/A0.00N/AN/AN/AN/AN/AN/AORICORIC Pharmaceuticals-$100.70M-$1.82N/AN/AN/AN/A-44.54%-40.72%5/5/2025 (Estimated)RLAYRelay Therapeutics-$341.97M-$2.39N/AN/AN/AN/A-45.75%-40.75%5/1/2025 (Estimated)Latest ENTA, RLAY, OPT, and ORIC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/26/2025Q4 2024RLAYRelay Therapeutics-$0.57-$0.45+$0.12-$0.45$5.53 millionN/A2/18/2025Q4 2024ORICORIC Pharmaceuticals-$0.52-$0.51+$0.01-$0.51N/AN/A2/10/2025Q1 2025ENTAEnanta Pharmaceuticals-$1.16-$1.05+$0.11-$1.05$17.25 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthENTAEnanta PharmaceuticalsN/AN/AN/AN/AN/AOPTOptheaN/AN/AN/AN/AN/AORICORIC PharmaceuticalsN/AN/AN/AN/AN/ARLAYRelay TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioENTAEnanta PharmaceuticalsN/A5.475.47OPTOptheaN/A2.942.94ORICORIC PharmaceuticalsN/A10.5613.15RLAYRelay TherapeuticsN/A18.4218.42Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipENTAEnanta Pharmaceuticals94.99%OPTOpthea55.95%ORICORIC Pharmaceuticals95.05%RLAYRelay Therapeutics96.98%Insider OwnershipCompanyInsider OwnershipENTAEnanta Pharmaceuticals13.89%OPTOpthea3.20%ORICORIC Pharmaceuticals5.55%RLAYRelay Therapeutics4.32%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableENTAEnanta Pharmaceuticals16021.33 million18.37 millionOptionableOPTOpthea8153.91 million148.98 millionNot OptionableORICORIC Pharmaceuticals8071.03 million67.09 millionOptionableRLAYRelay Therapeutics330169.52 million160.15 millionOptionableENTA, RLAY, OPT, and ORIC HeadlinesRecent News About These CompaniesRelay Therapeutics, Inc. (NASDAQ:RLAY) CFO Thomas Catinazzo Sells 4,864 SharesApril 1 at 4:29 PM | marketbeat.comRelay Therapeutics, Inc. (NASDAQ:RLAY) CFO Sells $13,813.76 in StockApril 1 at 4:36 AM | insidertrades.comRelay Therapeutics (RLAY) Gets Analyst Boost as AI-Driven Drug Discovery Shines!March 31 at 3:39 PM | msn.comAnalysts Set Relay Therapeutics, Inc. (NASDAQ:RLAY) Target Price at $19.80March 30 at 1:31 AM | americanbankingnews.comRelay Therapeutics weakness brings buying opportunity, says BarclaysMarch 28, 2025 | markets.businessinsider.comRelay Therapeutics (NASDAQ:RLAY) Trading 6.1% Higher - Should You Buy?March 28, 2025 | marketbeat.comBIT Capital GmbH Acquires New Holdings in Relay Therapeutics, Inc. (NASDAQ:RLAY)March 28, 2025 | marketbeat.comRelay Therapeutics, Inc. (NASDAQ:RLAY) Given Consensus Recommendation of "Moderate Buy" by BrokeragesMarch 27, 2025 | marketbeat.comRelay Therapeutics (NASDAQ:RLAY) Sets New 52-Week Low - What's Next?March 26, 2025 | marketbeat.comRelay Therapeutics (NASDAQ:RLAY) Shares Down 3.2% - Should You Sell?March 20, 2025 | marketbeat.comRelay Therapeutics’ SWOT analysis: promising drug faces stiff competitionMarch 19, 2025 | investing.comRelay Therapeutics (NASDAQ:RLAY) Trading Down 6.7% - Should You Sell?March 14, 2025 | marketbeat.comRelay Therapeutics’ SWOT analysis: stock poised for growth amid challengesMarch 14, 2025 | investing.comHC Wainwright Reaffirms Buy Rating for Relay Therapeutics (NASDAQ:RLAY)March 8, 2025 | marketbeat.comCandriam S.C.A. Acquires 636,494 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY)March 8, 2025 | marketbeat.comRelay Therapeutics (NASDAQ:RLAY) Hits New 1-Year Low - Should You Sell?March 6, 2025 | marketbeat.comDown -31.1% in 4 Weeks, Here's Why You Should You Buy the Dip in Relay Therapeutics (RLAY)March 5, 2025 | zacks.comRelay Therapeutics (NASDAQ:RLAY) Shares Down 8.1% - Here's WhyMarch 4, 2025 | marketbeat.comRelay Therapeutics, Inc. (NASDAQ:RLAY) Receives Average Recommendation of "Moderate Buy" from BrokeragesMarch 2, 2025 | marketbeat.comRelay Therapeutics price target lowered to $12 from $21 at Citizens JMPFebruary 28, 2025 | markets.businessinsider.comBank of America Securities Sticks to Their Buy Rating for Relay Therapeutics (RLAY)February 28, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesOccidental Petroleum Drops to 52-Week Low: Buy, Sell, or Hold?By Thomas Hughes | March 6, 2025View Occidental Petroleum Drops to 52-Week Low: Buy, Sell, or Hold?Word-of-Mouth Winners: 2 Stocks Growing Without Big Ad BudgetsBy Leo Miller | March 21, 2025View Word-of-Mouth Winners: 2 Stocks Growing Without Big Ad BudgetsIntel Stock Surges on New CEO – The Real Story Runs DeeperBy Gabriel Osorio-Mazilli | March 13, 2025View Intel Stock Surges on New CEO – The Real Story Runs DeeperSuper Micro Stock: $7.2M Call Options Signal Big Upside PotentialBy Gabriel Osorio-Mazilli | March 24, 2025View Super Micro Stock: $7.2M Call Options Signal Big Upside Potential3 Stocks to Buy While Others Stay on the SidelinesBy Chris Markoch | March 8, 2025View 3 Stocks to Buy While Others Stay on the SidelinesENTA, RLAY, OPT, and ORIC Company DescriptionsEnanta Pharmaceuticals NASDAQ:ENTA$5.32 -0.20 (-3.62%) Closing price 04:00 PM EasternExtended Trading$5.32 0.00 (-0.09%) As of 04:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.Opthea NASDAQ:OPT$3.41 +0.23 (+7.23%) As of 03/31/2025Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead product candidate is Sozinibercept (OPT 302), a soluble form of vascular endothelial growth factor receptor-3 VEGFR-3, currently under Phase 3 clinical development as a novel therapy for wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.ORIC Pharmaceuticals NASDAQ:ORIC$5.53 -0.05 (-0.90%) Closing price 04:00 PM EasternExtended Trading$5.53 0.00 (0.00%) As of 06:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.Relay Therapeutics NASDAQ:RLAY$2.47 -0.15 (-5.73%) Closing price 04:00 PM EasternExtended Trading$2.48 +0.00 (+0.20%) As of 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas D-Wave: Multiple Use Cases Emerge Following Quantum Supremacy Amazon Falls Back to a Key Support Line: Here's How to Play It Berkshire Hathaway Gains Defy Stock Market Slump Tech Sell-Off Makes Microsoft Stock Look Like a Steal Palantir Stock Builds Momentum on New Partnership Amprius Market Gets Amped Up on Growth Outlook 3 Buyable Stocks With Solid Bottoms Ready to Rebound Game-Changing News for Advanced Micro Devices Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
